These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 16226710)

  • 1. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Nov; 337(1):1-13. PubMed ID: 16129412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transduction via the stem cell factor receptor/c-Kit.
    Rönnstrand L
    Cell Mol Life Sci; 2004 Oct; 61(19-20):2535-48. PubMed ID: 15526160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
    Ali S; Ali S
    Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal and oncogenic forms of the receptor tyrosine kinase kit.
    Lennartsson J; Jelacic T; Linnekin D; Shivakrupa R
    Stem Cells; 2005; 23(1):16-43. PubMed ID: 15625120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor.
    Samayawardhena LA; Hu J; Stein PL; Craig AW
    Cell Signal; 2006 Sep; 18(9):1447-54. PubMed ID: 16442778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
    Foster R; Griffith R; Ferrao P; Ashman L
    J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kit as a human oncogenic tyrosine kinase.
    Kitamura Y; Hirotab S
    Cell Mol Life Sci; 2004 Dec; 61(23):2924-31. PubMed ID: 15583854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process.
    Zou J; Wang YD; Ma FX; Xiang ML; Shi B; Wei YQ; Yang SY
    Proteins; 2008 Jul; 72(1):323-32. PubMed ID: 18214972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
    Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
    Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
    Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C
    Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT and mastocytosis.
    Lim KH; Pardanani A; Tefferi A
    Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.
    Beghini A; Bellini M; Magnani I; Colapietro P; Cairoli R; Morra E; Larizza L
    Exp Hematol; 2005 Jun; 33(6):682-8. PubMed ID: 15911092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.
    Yuzawa S; Opatowsky Y; Zhang Z; Mandiyan V; Lax I; Schlessinger J
    Cell; 2007 Jul; 130(2):323-34. PubMed ID: 17662946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
    Tuveson DA; Willis NA; Jacks T; Griffin JD; Singer S; Fletcher CD; Fletcher JA; Demetri GD
    Oncogene; 2001 Aug; 20(36):5054-8. PubMed ID: 11526490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-function analyses of the kit receptor for the steel factor.
    Blechman JM; Lev S; Givol D; Yarden Y
    Stem Cells; 1993 Jul; 11 Suppl 2():12-21. PubMed ID: 7691317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility.
    Blume-Jensen P; Jiang G; Hyman R; Lee KF; O'Gorman S; Hunter T
    Nat Genet; 2000 Feb; 24(2):157-62. PubMed ID: 10655061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
    Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
    J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.